JLR: Virtual issue sheds light on a key risk factor for heart disease
Because lipids such as cholesterol and triglycerides are hydrophobic and tend to clump up, rather than dissolve, in water, they need help getting around inside the body. Lipoproteins are complex assemblies with hydrophilic outer shells that package hydrophobic lipids in their core, allowing them to hitch a ride through the bloodstream. These delivery particles play an important role in the absorption of dietary lipids from the small intestine and also transport lipids to and from the liver.
The cover of the JLR virtual issue depicts the Lp(a) particle following the steps of a walking path, getting bigger as the road stretches into infinity.
High levels of one particular class of lipoprotein, known as lipoprotein (a), are associated with atherosclerosis, inflammation and thrombosis, but no treatments are available in the clinic that specifically lower Lp(a), and much of what governs Lp(a) assembly is still unknown.
A new virtual issue from the Journal of Lipid Research titled “Lipoprotein (a): Many strides made, yet there is a long road ahead” explores the past, present and future status of Lp(a) research and showcases researchers pushing this field forward. This issue was assembled by JLR Junior Associate Editor Gissette Reyes-Soffer from Columbia University Irving Medical Center in New York City.
Several papers collected in this issue offer insights into how various Lp(a)-reducing drugs work. In one of these studies, Enkhmaa Byambaa and colleagues at the University of California, Davis, and the University of Hong Kong demonstrated that alirocumab — an inhibitor of the lipid-binding enzyme PCSK9 — could lower Lp(a) levels regardless of the isoform of proteins in Lp(a).
A study by Frederick Raal and an international team of researchers suggests that another PCSK9 inhibitor, evolocumab, reduces Lp(a) levels partly by increasing the expression of LDL receptors.
Elisa Waldmann and Klaus Parhofer at Ludwig Maximilian University of Munich wrote a review that discusses apheresis as an effective method of selectively clearing Lp(a) from the blood and reducing risk of cardiovascular disease.
Another review, penned by George Thanassoulis at McGill University, describes the association of Lp(a) with aortic valve disease and outlines steps toward developing much-needed preventive and therapeutic strategies.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Latest in Science
Science highlights or most popular articles
Finding a third form of fat
When brown fat was discovered in human adults, it came as a surprise. A classic JBC study found another surprise: White fat cells could be coaxed into a phenotype resembling brown fat.
My cat’s coat is mostly white with dark tabby patches. What’s going on?
A researcher uses a tweetorial to figure out the underlying genetics for their cat’s coat.
Dalit scientists face barriers in India’s top science institutes
Despite decades-old inclusion policies, Dalits are systematically underrepresented in science institutes in India. Why?
‘It goes both ways’
This year’s theme of “location, location, location” refers to the scenic meeting spot and to a new way of looking at lipids.
From the journals: JLR
Predicting drug-induced lysosomal fat buildup. Minimizing side effects of atherosclerosis treatment. Finding a key to sepsis diagnosis and treatment. Read about papers on these topics recently published in the Journal of Lipid Research.
A new way of looking at concussions
Emerging research suggests that even mild hits to the head may damage the tiny lymphatic vessels that clear toxic chemicals and cellular debris from the brain.